Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.

Volume: 10, Issue: 3, Pages: 310 - 319
Published: Jun 1, 2017
Abstract
Background. Atypical haemolytic uraemic syndrome (aHUS) is a rare, life-threatening disorder for which eculizumab is the only approved treatment. Life-long treatment is indicated; however, eculizumab discontinuation has been reported. Methods. Unpublished authors' cases and published cases of eculizumab discontinuation are reviewed. We also report eculizumab discontinuation data from five clinical trials, plus long-term extensions and the global...
Paper Details
Title
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
Published Date
Jun 1, 2017
Journal
Volume
10
Issue
3
Pages
310 - 319
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.